Coinfections and superinfections associated with COVID-19 in Colombia: A narrative review
D Dueñas, J Daza, Y Liscano - Medicina, 2023 - mdpi.com
The COVID-19 pandemic has had significant impacts on healthcare systems around the
world, including in Latin America. In Colombia, there have been over 23,000 confirmed …
world, including in Latin America. In Colombia, there have been over 23,000 confirmed …
Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of COVID-19: A Literature Review with a Focus on Real-World Evidence
I Karniadakis, N Mazonakis, C Tsioutis… - Infectious Disease …, 2023 - mdpi.com
Vaccines remain the cornerstone of medical prevention and are highly effective in reducing
the risk of severe disease and death due to coronavirus disease 2019 (COVID-19). In the …
the risk of severe disease and death due to coronavirus disease 2019 (COVID-19). In the …
N4-hydroxycytidine, the active compound of Molnupiravir, promotes SARS-CoV-2 mutagenesis and escape from a neutralizing nanobody
A Zibat, X Zhang, A Dickmanns, KM Stegmann… - Iscience, 2023 - cell.com
Summary N4-hydroxycytidine (NHC), the active compound of the drug Molnupiravir, is
incorporated into SARS-CoV-2 RNA, causing false base pairing. The desired result is an" …
incorporated into SARS-CoV-2 RNA, causing false base pairing. The desired result is an" …
Molnupiravir Revisited—Critical Assessment of Studies in Animal Models of COVID-19
HB Rasmussen, PR Hansen - Viruses, 2023 - mdpi.com
Molnupiravir, a prodrug known for its broad antiviral activity, has demonstrated efficacy in
animal models of COVID-19, prompting clinical trials, in which initial results indicated a …
animal models of COVID-19, prompting clinical trials, in which initial results indicated a …
Quality control in SARS-CoV-2 RBD-Fc vaccine production using LC–MS to confirm strain selection and detect contaminations from other strains
P Suwanchaikasem, K Rattanapisit, R Strasser… - Scientific Reports, 2024 - nature.com
Abstract Coronavirus disease of 2019 (COVID-19), caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), is an ongoing outbreak, disrupting human life …
syndrome coronavirus 2 (SARS-CoV-2), is an ongoing outbreak, disrupting human life …
[HTML][HTML] Japan's COVID‐19 treatment strategy: an examination of approved oral medications
Y Higuchi, Y Kaneda, T Tanimoto - Clinical and Translational …, 2023 - ncbi.nlm.nih.gov
This study scrutinizes Japan's coronavirus disease 2019 (COVID-19) medication policy,
focusing on three approved oral drugs: molnupiravir, nirmatrelvir, and ensitrelvir. The study …
focusing on three approved oral drugs: molnupiravir, nirmatrelvir, and ensitrelvir. The study …
Effectiveness of nirmatrelvir/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review and meta-analysis of observational studies
Objective To determine the effectiveness of nirmatrelvir/ritonavir and molnupiravir among
vaccinated and unvaccinated non-hospitalized adults with COVID-19. Methods …
vaccinated and unvaccinated non-hospitalized adults with COVID-19. Methods …
Nirmatrelvir/ritonavir for COVID-19: an overview of systematic reviews
M Cruciani, I Pati, F Masiello, S Pupella… - Journal of …, 2024 - academic.oup.com
Objectives A reappraisal of the validity of the conclusions of systematic reviews (SRs)
related to nirmatrelvir/ritonavir for the treatment of COVID-19. Methods An overview of SRs …
related to nirmatrelvir/ritonavir for the treatment of COVID-19. Methods An overview of SRs …
Comparison of effectiveness and safety of molnupiravir versus sotrovimab for COVID‐19: A systematic review and meta‐analysis
Abstract Background and Aim This systematic review and meta‐analysis aimed to compare
the effectiveness and safety of molnupiravir and sotrovimab in the treatment of patients with …
the effectiveness and safety of molnupiravir and sotrovimab in the treatment of patients with …
[HTML][HTML] Oral antivirals for COVID-19 among patients with cancer
D Guermazi, P Arvanitis, K Vieira, JL Warner… - Research …, 2024 - ncbi.nlm.nih.gov
Purpose: Immunocompromised individuals, such as those diagnosed with cancer, are at a
significantly higher risk for severe illness and mortality when infected with SARS-CoV-2 …
significantly higher risk for severe illness and mortality when infected with SARS-CoV-2 …